22 April 2018

TIKOMED IS INTERVIEWED AT BIOSPRING ABOUT IBSOLVMIR FOR IMPROVED CELL-THERAPIES BY MIKE WARD

TikoMeds promising Phase 2 project for more efficient cell-therapies was presented at BioEurope Spring in Amsterdam. Below follows an interview by Mike Ward of Adam Bruce, Founder and CEO of TikoMed.

DATE
TBA

TIME
TBA

VENUE
TBA

OTHER NEWS

20 August 2018
TIKOMED to initiate ALS clinical trial for which the UK Medicines and Healthcare products Regulatory Agency has granted permission
Viken, August 20th, 2018 — TIKOMED, a specialty pharmaceutical company focused on developing therapeutics for…
Read More
14 August 2018
TIKOMED Announce Start of ALS Study at Sahlgrenska University Hospital
VIKEN, Sweden, August 14, 2018 – ​TIKOMED, a specialty pharmaceutical company focused on developing therapeutics…
Read More
24 July 2018
TIKOMED is looking for an experienced Project Leader
We are looking for you who are passionate, skilled and with strong track record and…
Read More
SEE MORE